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Abstract
Background: Ixabepilone (BMS-247550), an epothilone B analog, is a microtubule stabilizing agent which has shown activity
in several different tumor types and preclinical models in melanoma. In an open label, one-arm, multi-center phase II trial
the efficacy and toxicity of this epothilone was investigated in two different cohorts: chemotherapy-naı ¨ve (previously
untreated) and previously treated patients with metastatic melanoma.
Methodology/Principal Findings: Eligible patients had histologically-confirmed stage IV melanoma, with an ECOG
performance status of 0 to 2. Ixabepilone was administered at a dose of 20 mg/m
2 on days 1, 8, and 15 during each 28-day
cycle. The primary endpoint was response rate (RR); secondary endpoints were time to progression (TTP) and toxicity.
Twenty-four patients were enrolled and 23 were evaluable for response. Initial serum lactate dehydrogenase (LDH) levels
were elevated in 6/11 (55%) of the previously treated and in 5/13 (38%) of the previously untreated patients. No complete
or partial responses were seen in either cohort. One patient in the previously treated group developed neutropenia and
fatal septic shock. Seventeen patients (8 in the previously untreated group and 9 in the previously treated group)
progressed after 2 cycles, whereas six patients (3 in each group) had stable disease after 2–6 cycles. Median TTP was 1.74
months in the previously untreated group (95% CI=1.51 months, upper limit not estimated) and 1.54 months in the
previously treated group (95% CI=1.15 months, 2.72 months). Grade 3 and/or 4 toxicities occurred in 5/11 (45%) of
previously untreated and in 5/13 (38%) of previously treated patients and included neutropenia, peripheral neuropathy,
fatigue, diarrhea, and dyspnea.
Conclusions/Significance: Ixabepilone has no meaningful activity in either chemotherapy-naı ¨ve (previously untreated) or
previously treated patients with metastatic melanoma. Further investigation with ixabepilone as single agent in the
treatment of melanoma is not warranted.
Trial registration: Clinical Trials.gov NCT00036764
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Introduction
There is an urgent need for the identification of active
agents in metastatic melanoma. In addition to dacarbazine,
temozolomide, and the platinum analogs, the taxanes have shown
activity in metastatic melanoma, with overall response rates
(RR) in the range of 12%–17% when used as single agents
[1,2,3,4,5,6,7]. The epothilones are naturally occurring macro-
lides produced by the myxobacteria Sorangium cellulosum. Like
taxanes, their mechanism of action involves the stabilization of
microtubules that are necessary for DNA replication and cell
division. The exact binding sites on microtubules of taxanes and
epothilones overlap but are not identical; however, the microtu-
bule polymerization activity of epothilone B is higher compared
to paclitaxel [8]. In vitro studies have demonstrated that
epothilones have more potent growth inhibition of human
prostate, breast, lung, colon, and bladder carcinoma cell lines
than the taxanes [9]. An even more marked sensitivity to
epothilone B relative to paclitaxel was recently shown in two
human melanoma cell lines [10]. Furthermore, the epothilone
sagupilone has demonstrated superior efficacy compared to
paclitaxel and temozolomide in a mouse CNS metastasis model
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lone resulted in tumor regression in a mouse B16 melanoma
model [12].
Ixabepilone (BMS-247550), a semi-synthetic analog of the
natural product epothilone B, has been examined in several phase
II clinical trials including patients with hormone refractory
prostate cancer [13,14], non-small lung cancer [15], and head
and neck cancer [16], amongst others. It was recently approved
by the FDA for the treatment of taxane-refractory metastatic
breast cancer after a phase III trial showed a significantly longer
median time to progression when used in combination with
capecitabine compared to capecitabine alone [17]. Adverse
events of ixabepilone observed in these studies included
hematological toxicities, sensory neuropathy, myalgia, arthralgia,
fatigue and diarrhea.
These preclinical and clinical observations provided the
rationale to initiate a phase II trial of ixabepilone to assess its
efficacy in the treatment of metastatic melanoma.
Results
Participant Flow
The flow of participants through each stage of the study is
illustrated in Fig. 1.
One patient had no follow-up disease status evaluation due to
death from septic shock after the first cycle of treatment.
Recruitment
Between March of 2002 and October of 2003, 24 patients were
enrolled at 5 centers in the United States and Australia. Patients
were followed until disease progression or discontinuation of
treatment due to unacceptable side effects, intercurrent illness, or
patient withdrawal.
Baseline Data
Pre-treatment characteristics of the study population are listed
in Table 1. All but one patient had an ECOG performance status
Figure 1. Consort diagram.
doi:10.1371/journal.pone.0008714.g001
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untreated patient group and 52 (range 37–62 years) in the
previously treated group. Of the 11 previously untreated patients,
6 had primary cutaneous melanoma, one had orbital melanoma,
one had ocular melanoma, and 3 had unknown primary
melanoma. Of the 13 previously treated patients, 11 had primary
cutaneous melanoma and 2 had unknown primary melanoma.
Ten of the previously treated patients had received one line of
prior chemotherapy and 3 had received 2 lines. All patients with
known primary tumor had undergone resection of the tumor. Five
of eleven (45%) of previously untreated and 8/13 (62%) of
previously treated patients were stage M1c. All patients in the
previously treated group had been treated with single agent
dacarbazine or temozolomide.
Numbers Analyzed
Eleven patients were enrolled in the previously untreated group.
In the previously treated group, one additional patient as
replacement for a patient who was not evaluable for response
due to toxicity and death from neutropenic sepsis was enrolled, for
a total of 13 (instead of the planned 12).
Outcomes and Estimation
A total of 59 cycles of chemotherapy was administered during
the study; the median number of cycles was 2 (range 1–6) in both
patient groups. All patients in both subgroups completed at least
one cycle of treatment. Treatment was discontinued for disease
progression in 73% of patients in the previously untreated cohort
and in 69% of patients in the previously treated subgroup. All 11
patients in the previously untreated group and 12 of the 13
patients in the previously treated group were assessable for
response, whereas all patients in both groups were assessable for
toxicity. No complete response (CR) or partial response (PR) were
observed in either patient group (95% confidence intervals: 0–28
for the previously untreated group, 0–26 for the previously treated
group, Table 2). Three patients had stable disease (SD) for 2–6
cycles in each cohort, respectively. Median TTP was 1.74 months
in the previously untreated group (95% CI=1.51 months, upper
limit not estimated) and 1.54 months in the previously treated
group (95% CI=1.15 months, 2.72 months) (Fig 2). One patient
with SD in each group stopped treatment due to grade 3
peripheral neuropathy: one after 3 cycles (previously untreated)
and the other one after 2 cycles (previously treated). One patient in
the previously treated group who had SD refused further
treatment after completing 3 cycles. He had not experienced
any significant adverse events during treatment. The remaining 2
patients in the previously untreated group completed six cycles
without significant adverse events; one had SD in lung and muscle
lesions, while the other had stable lung and skin lesions as well as
hilar and abdominal lymphadenopathy, respectively.
According to the stopping rules of the 3-stage design (Table 3),
accrual was terminated after stage one, since no responses were
seen in either of the 2 cohorts.
Adverse Events
All patients were evaluable for safety. Overall, grade 3 and/or 4
toxicities occurred in 5/11 (45%) of previously untreated and in 5/
13 (38%) of previously treated patients. The hematological and
non-hematological adverse events experienced by the patients in
this trial are summarized in Table 4. Grade 3 and 4 neutropenia
occurred in 1/11 (9%) of previously untreated and in 3/13 (23%)
of previously treated patients. The predominant non-hematolog-
ical toxicities were neuropathy, diarrhea, dyspnea, and fatigue in
both cohorts. The incidence of neuropathy was 55% (all grades)








Enrolled Total 11 100 13 100
Sex
Male 7 64 8 62





Caucasian 10 91 13 100
Asian 1 9 0 0
ECOG Performance Status
05 4 5 7 5 4
16 5 5 5 3 8
20 0 1 8
LDH
Within Normal Limits 5 45 8 62
Elevated 6 55 5 38
M-Stage
M1a 2 18 2 15
M1b 4 36 3 23
M1c 5 45 8 62
Prior Immunotherapy 5 45 5 38
Prior Chemotherapy 0 0 13 100
Single Agent 10 77
Multiple Agents 3 23




Table 2. Summary of treatment and responses.
1Cohort A
2Cohort B





% 95% CI No. of
patients
% 95% CI
Assessable for response (n) 11 100 12 100
Complete Response 0 0 0–28 0 0 0–26
Partial Response 0 0 0–28 0 0 0–26
Stable disease 3 27 3 25
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(all grades) and 8% (grade 3) in the previously treated subgroup.
Treatment had to be terminated for grade 3 neuropathy during
cycle 2 for one patient in the previously untreated group and
during cycle 3 for one patient in the previously treated cohort. Six
of the 11 (55%) patients in the previously untreated group and 4/
13 (31%) patients in the previously treated group developed
diarrhea, which was generally easily manageable and did not result
in treatment termination for any of the patients. Fatigue occurred
in 6/11 (55%) of the patients in the previously untreated subgroup
and in 9/13 (69%) of the patients in the previously treated
subgroup, but was grade 3 in only one patient in the previously
untreated group and did not lead to treatment cessation. There
was one death in which treatment was implicated. The patient,
who was in the previously treated group of the study, developed
febrile neutropenia, thrombocytopenia, and a suspected stroke
after the first cycle of chemotherapy and died during cycle 1 as a
result of septic shock.
Discussion
A major interest in clinical trials has been the efficacy of
epothilones in taxane-resistant cancers. The known activity of
epothilones in other solid tumors provided the rationale to charac-
terize the activity of an epothilone in metastatic melanoma patients.
This was the first trial conducted assessing the activity of
ixabepilone in melanoma patients. Ixabepilone as a single agent
did not show activity in the group of patients with metastatic
melanoma enrolled in our study. The absence of an objective
response was disappointing since taxanes used as single agents do
have activity in metastatic melanoma with RR comparable to
dacarbazine in phase II trials. Apart from breast cancer, clinical
activity has been demonstrated for ixabepilone in a variety of
tumor types with RR generally in the 10–20% range
[13,14,15,16,18,19,20]. Gene expression levels of the microtubule
associated protein tau have recently been described as inversely
correlated with response to epothilones in breast cancer patients
[21]. We speculate that tau expression levels might be higher in
advanced melanoma patients as compared to other solid tumors.
The major toxicities of ixabepilone in this trial were neutropenia,
peripheral neuropathy, diarrhea, dyspnea, and fatigue. Two
patients (8%) discontinued protocol therapy because of grade 3
neuropathy. Neuropathy has been a prominent side effect in
previous phase II and phase III trials with a frequency of grade 3
neuropathy in the 5–20% range [14,15,16,22,23,24]. Furthermore,
one patient died from neutropenic sepsis. A relatively high degree of
bone marrow suppression has been reported previously with the use
of ixabepilone as a single agent [19,25].
The high incidence of grade 3/4 neuropathy and myelosuppres-
sion is troubling. In retrospect, the optimal dosing protocol for
ixabepilone had not yet been fully established at the time of this trial
Figure 2. Kaplan-Meier analysis of time to progression.
1Cohort A: no previous chemotherapy;
2Cohort B: up to two prior chemotherapeutic
regimens.
doi:10.1371/journal.pone.0008714.g002
Table 3. Three-stage patient accrual.
Accrual
Stage
Number of Patients to
be accrued in Stage
Cumulative Number
of Patients accrued






1 11 11 0/11
2 18 29 3/29
3 21 50 7/50
2Cohort B
1 12 12 0/12
2 13 25 1/25
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2 on a 3-
weekly schedule, but protocols have also used lower doses given for
several days on a 3-week cycle. A dose of 20 mg/m
2 on a weekly
schedule for 3 weeks of a 4 week cycle was established in a phase I
dose escalation study; it was this dose schedule that was
recommended for phase II trials in cancers with no established
standard chemotherapy [26] and was chosen for this study. The
median number of treatment cycles administered to patients in this
study was lower than in other single agent ixabepilone trials (2 vs. 3–
5), suggesting that neuropathy and myelosuppression could be
underestimated compared to other studies. This would suggest a
higher toxicity of the weekly schedule, which has been associated
previously with an increased rate of side effects compared to every 3
week regimens [16].
In conclusion, ixabepilone as a single agent has no detected
activity in patients with metastatic melanoma and has a relatively
severe toxicity profile compared to agents currently in use for this
disease such as temozolomide, dacarbazine, paclitaxel, and carbo-
platin. Based on these data, further development of ixabepilone as
monotherapy is not warranted in patients with metastatic melano-
ma. Given the documented activity of microtubule stabilizing agents
in melanoma and the preclinical data documenting efficacy of
epothilones in melanoma cell lines, it is reasonable to project that
newer-generation epothilones, as they are being developed [27],
might still have a role in the future treatment of melanoma.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Ethics
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The protocol (NCI study number
NCI-4470, Clinical Trials.gov identifier NCT00036764) received
prior approval by the institutional review board at New York
University Langone Medical Center. The protocol was reviewed
by the local institutional review board at each participating
institution, and all patients provided written informed consent.
Participants
Eligible patients had histologically or cytologically confirmed
metastatic melanoma, with an Eastern Cooperative Oncology
Group (ECOG) performance status of 0 to 2. Life expectancy of
greater than 3 months was required, and patients were at least 18
years of age. All patients had measurable disease according to the
international criteria proposed by the Response Evaluation
Criteria in Solid Tumors (RECIST) committee [28]. Two different
subgroups were studied in a single arm phase II study: 1) patients
who were chemotherapy naı ¨ve (previously untreated) and 2)




Adverse Event 1 2 3 4 3/4 1 2 3 4 3/4
Number of patients (%)
Hematological
Leukopenia 0 1 (9) 0 0 0 0 0 1 (8) 1 (8) 2 (15)
Neutropenia 0 0 1 (9) 0 1 (9) 0 1 (8) 1 (8) 2 (15) 3 (23)
Anemia 1 (9) 1 (9) 1 (9) 0 1 (9) 0 0 0 0 0
Thrombocytopenia 0 0 0 0 0 0 0 0 1 (8) 1 (8)
Non-hematological
Anxiety 0 0 1 (9) 0 1 (9) 0 0 0 0 0
Neuropathy 3 (27) 2 (18) 1 (9) 0 1 (9) 4 (31) 0 1 (8) 0 0
H y p o t e n s i o n 0001 ( 9 ) 1 ( 9 ) 00000
Arrythmia 0 0 0 1 (9) 1 (9) 0 0 0 0 0
Fatigue 4 (36) 1 (9) 1 (9) 0 1 (9) 4 (31) 5 (38) 0 0 0
Dyspnea 0 0 1 (9) 0 1 (9) 0 2 (15) 1 (8) 0 1 (8)
Diarrhea 1 (9) 1 (9) 4 (36) 0 4 (36) 4 (31) 0 0 0 0
Constipation 0 0 0 0 0 0 0 1 (8) 0 1 (8)
Abdominal distension 0 0 0 0 0 0 0 1 (8) 0 1 (8)
Gastritis 0 1 (9) 0 0 0 0 0 0 0 0
Nausea 4 (36) 2 (18) 0 0 0 0 2 (15) 0 0 0
Anorexia 0 0 0 0 0 0 1 (8) 0 0 0
Pneumonitis 0 0 0 0 0 0 0 1 (8) 0 1 (8)
Infection 0 0 0 0 0 0 1 (8) 0 0 0
Alopecia 2 (18) 0 0 0 0 1 (8) 2 (15) 0 0 0
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lines of chemotherapy with mandatory dacarbazine or temolozo-
mide (previously treated). Patients with known brain metastases
were included in the study if they were steroid independent with
radiographically stable lesions for at least six weeks after whole
brain radiation and no mass effect present radiographically at the
time of study entry. Other eligibility criteria were normal
laboratory values (absolute neutrophil count of $1.5610
9/L,
platelets $100610
9/L, total bilirubin within normal institutional
limits, AST and ALT #2.5 times the upper limits of normal, and
creatinine #1.5 times the upper limit of normal). All women of
childbearing age had to agree to use contraception prior to study
entry and for the duration of study; pregnant women were
excluded. Patients who were receiving any other investigational
agents were excluded from the study. Exclusion criteria also
consisted of a history of severe allergic reactions (grade III or IV or
grade II not responsive to corticosteroids) attributed to medica-
tions containing Cremophor. Patients with pre-existing grade II–
IV peripheral neuropathy were excluded. Other exclusion criteria
comprised patients with uncontrolled concomitant illness including
but not limited to ongoing or active infection, HIV+ on anti-
retroviral therapy, symptomatic congestive heart failure, unstable
angina pectoris, cardiac arrhythmia, or psychiatric illness that
would limit compliance with study requirements.
The study was conducted by the New York Cancer Consortium
(www.newyorkcancerconsortium.org). The participating institu-
tions were New York University Langone Medical Center, New
York, NY, New York Presbyterian Hospital, New York, NY, Fox
Chase Cancer Center, Philadelphia, PA, Austin, Repatriation
Medical Centre, Melbourne, Australia, and Sydney Cancer
Center, Sydney, Australia. The study was reviewed, approved,
and sponsored by the Cancer Therapy Evaluation Program of the
National Cancer Institute.
Interventions
Ixabepilone was evaluated as a single agent in patients with
stage IV malignant melanoma. All patients were treated with
ixabepilone at 20 mg/m
2 administered as a 1 hour infusion on
days 1, 8, and 15 of each 28-day cycle. This dosing regimen (rather
than the more commonly used 40 mg/m
2 every 3 weeks) was
chosen based on phase I data in patients with advanced
malignancy with no standard treatment options [26]. Patients
received premedication with diphenhydramine 50 mg i.v., ranit-
idine 50 mg i.v., ondansetron 8 mg i.v./po., and dexamethasone
20 mg i.v. to minimize nausea, vomiting, and hypersensitivity
reactions. Treatment was stopped at any time point due to disease
progression or intolerable side effects. Adverse events were
reported using the revised NCI Common Toxicity Criteria
(CTC) version 3.0. Hematologic growth factors were not used
prophylactically in this study, but were used at the discretion of the
investigator in the event of severe hematologic toxicity.
Objectives
The objectives of this phase II trial were to assess the efficacy of
ixabepilone in metastatic melanoma patients and to expand upon
the known toxicity profile of ixabepilone at the recommended
phase II dose. The hypothesis, based on preclinical data in
melanoma cell lines and a mouse model, was that ixabepilone has
efficacy in metastatic melanoma patients.
Outcomes
The primary endpoint was objective RR, while time to tumor
progression (TTP) and toxicity were assessed as secondary
endpoints. Response and progression were evaluated in this study
using RECIST criteria [28]. Complete history and physical
examination, assessment of ECOG performance status, routine
laboratory studies and appropriate imaging studies to evaluate the
extent of metastatic disease were performed at enrollment. Patients
were assessable for response if they received one or more cycles of
treatment; treatment response was evaluated every two cycles
using appropriate radiographic imaging studies, complete history
and physical examinations, and routine laboratory studies. Time
to progression was defined as the time from the first day of
treatment with ixabepilone until the first documentation of disease
progression. For patients who did not progress, the date of last
follow-up was used to censor the patients at that point. Patients
were treated until disease progression or development of
unacceptable toxicities.
Sample Size and Statistical Design
The three-stage optimal design for phase II clinical trials
proposed by Ensign et al. [29] was used in each subgroup (group
A: previously untreated, group B: previously treated with
chemotherapy). We projected that ixabepilone would have a RR
of 10% in the previously untreated and 5% in the previously
treated group, below which the response would be unacceptable,
and a RR of 25% in the previously untreated and 20% in the
previously treated group, above which the regimen would be
considered worthy of further exploration. The null hypothesis that
the overall response proportion would be less than or equal to 10%
(for the previously untreated group) and 5% (for the previously
treated group) was tested against the alternative hypothesis that the
response proportion would be greater than or equal to 25% (for
the previously untreated group) and 20% (for the previously
treated group).
The statistical design and planned 3-stage patient accrual,
including the numbers of patients to be accrued at each stage in
both subgroups is described in Table 3. A total sample size of 23–
88 evaluable patients was planned. Using this design, both the
alpha and beta error probabilities were 0.10 for both cohorts. The
alpha level being used was one-sided. A beta error probability of
0.10 (lower than the commonly used 0.20) was chosen because of
the paucity of new drugs that may be active in melanoma. No
formal comparison between the 2 subgroups was planned or
performed.
Descriptive statistics and percentages are presented for demo-
graphic and clinical characteristics. TTP was analyzed using the
Kaplan-Meier method. Ninety-five percent confidence intervals
(95% CI) for median TTP and the observed RR were calculated to
assess the precision of the obtained estimates. All analyses were
performed in SAS version 9.1 (SAS Institute, Inc., Cary, NC) and
Stata version 10.0 (Stata Corporation, College Station, TX).
Supporting Information
Protocol S1 Trial Protocol.
Found at: doi:10.1371/journal.pone.0008714.s001 (0.55 MB
DOC)
Checklist S1 CONSORT Checklist.
Found at: doi:10.1371/journal.pone.0008714.s002 (0.19 MB
DOC)
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